Anti-Cancer Drugs — Part 1

Correct Answer

B — Topoisomerase I inhibitor

Rationale

Irinotecan is classified as a topoisomerase I inhibitor and is a semisynthetic derivative of the plant alkaloid camptothecin. It stabilizes the topoisomerase I cleavable complex, preventing relegation of the single-strand nick and ultimately generating lethal double-strand breaks when replication forks collide with the stabilized complex. Anthracyclines (doxorubicin, epirubicin) inhibit topoisomerase II and generate reactive oxygen species. Epipodophyllotoxins (etoposide, teniposide) inhibit topoisomerase II. Glycopeptide antitumor antibiotics (bleomycin) kill cells through oxidative deoxyribonucleic acid strand scission.

Correct Answer

A — Epipodophyllotoxin topoisomerase II inhibitor

Rationale

Etoposide is classified as an epipodophyllotoxin and acts as a topoisomerase II inhibitor. It stabilizes the topoisomerase II-alpha cleavable complex at the G2 phase and G2/M boundary, generating persistent double-strand breaks and triggering apoptosis. Camptothecin derivatives (irinotecan, topotecan) are topoisomerase I inhibitors. Anthracyclines (doxorubicin, epirubicin) also inhibit topoisomerase II but are structurally and pharmacologically distinct from epipodophyllotoxins. Alkylating agents form covalent deoxyribonucleic acid adducts through an entirely different mechanism.

Correct Answer

C — Anthracycline

Rationale

Doxorubicin is classified as an anthracycline. Anthracyclines are a class of antitumor antibiotics derived from Streptomyces species that exert cytotoxicity through multiple simultaneous mechanisms including topoisomerase II-alpha cleavable complex stabilization, reactive oxygen species generation, and cardiolipin binding at the mitochondrial inner membrane. Camptothecin derivatives (irinotecan, topotecan) are topoisomerase I inhibitors. Epipodophyllotoxins (etoposide, teniposide) are topoisomerase II inhibitors with a different mechanism and structure. Alkyl sulfonates (busulfan) are alkylating agents.

Correct Answer

D — Glycopeptide antitumor antibiotic

Rationale

Bleomycin is classified as a glycopeptide antitumor antibiotic. It kills cells not by inhibiting topoisomerases but by chelating iron and generating reactive oxygen species that directly cleave deoxyribonucleic acid strands, preferentially at guanine-cytosine and guanine-thymine sequences. Bleomycin hydrolase, which inactivates bleomycin, is expressed at low levels in lung and skin — explaining the drug's characteristic organ-specific toxicities. Anthracyclines (doxorubicin) and epipodophyllotoxins (etoposide) both inhibit topoisomerase II but through entirely different structural mechanisms. Topoisomerase I inhibitors (irinotecan, topotecan) are camptothecin derivatives.

Correct Answer

B — Antitumor antibiotic that inhibits transcription

Rationale

Actinomycin D (dactinomycin) is classified as an antitumor antibiotic that inhibits transcription. It intercalates into double-stranded deoxyribonucleic acid by inserting its phenoxazinone chromophore between guanine-cytosine base pairs, physically blocking ribonucleic acid polymerase movement along the template and inhibiting synthesis of all ribonucleic acid species. It does not inhibit topoisomerase I or topoisomerase II as its primary mechanism and is not an anthracycline, though it shares the antitumor antibiotic classification with doxorubicin. Its transcription inhibition distinguishes it from all topoisomerase-targeting agents and makes it a potent radiation sensitizer by blocking transcription of deoxyribonucleic acid repair enzymes.

Correct Answer

C — Liposomal anthracycline formulation that exploits tumor vascular permeability to reduce cardiotoxicity

Rationale

Pegylated liposomal doxorubicin is classified as a liposomal anthracycline formulation. Doxorubicin is encapsulated in polyethylene glycol-coated liposomes that exploit the enhanced permeability and retention effect — the disordered and leaky vasculature of tumors allows preferential extravasation of nano-scale liposomal particles, while normal capillaries retain them, reducing systemic drug exposure to normal tissues including the myocardium. This formulation strategy substantially reduces cardiotoxicity compared with conventional doxorubicin while preserving antitumor activity, though it introduces different toxicities including palmar-plantar erythrodysesthesia and mucositis as the dose-limiting effects. It contains doxorubicin and retains the anthracycline mechanism of action.

Correct Answer

C — Irinotecan is a prodrug converted by hepatic enzymes to SN-38, the active metabolite that inhibits topoisomerase I and causes cytotoxic strand breaks in genetic material

Rationale

Irinotecan is a prodrug. After administration, hepatic enzymes cleave the molecule to release SN-38, the pharmacologically active metabolite. SN-38 inhibits topoisomerase I by stabilizing the enzyme-strand cleavage complex, preventing re-ligation of strand breaks and causing replication fork collapse and cell death. Because SN-38 is generated hepatically rather than at the tumor site, plasma SN-38 levels reflect hepatic conversion efficiency and are subject to pharmacogenomic variation. Irinotecan is not activated by topoisomerase I itself, does not undergo spontaneous plasma hydrolysis to yield SN-38, and does not require intracellular phosphorylation.

Correct Answer

D — The early syndrome is cholinergic, caused by acetylcholinesterase inhibition by irinotecan, and responds to atropine; the late syndrome is caused by intraluminal SN-38 mucosal toxicity after bacterial deconjugation of biliary SN-38 glucuronide, and responds to loperamide

Rationale

Irinotecan produces two mechanistically distinct diarrhea syndromes requiring different treatments. Early diarrhea, occurring during or within 24 hours of infusion, is cholinergic in mechanism: irinotecan inhibits acetylcholinesterase, producing excess acetylcholine at muscarinic receptors with cramping, diaphoresis, flushing, lacrimation, and diarrhea. Treatment is atropine. Late diarrhea, beginning more than 24 hours after infusion, is caused by SN-38 mucosal toxicity: SN-38 glucuronide is excreted in bile, and intestinal bacterial beta-glucuronidases deconjugate it back to active SN-38 in the lumen, causing direct mucosal injury. Treatment is high-dose loperamide. Confusing the two syndromes — using loperamide for early diarrhea or atropine for late diarrhea — is a treatment failure that can progress to fatal dehydration.

Correct Answer

A — Reduced UGT1A1 activity impairs glucuronidation of SN-38, causing the active metabolite to accumulate to higher concentrations and produce excessive toxicity

Rationale

SN-38 is inactivated by glucuronidation, a reaction catalyzed by UGT1A1. Patients with reduced UGT1A1 activity cannot inactivate SN-38 at the normal rate; the active metabolite accumulates to higher plasma concentrations than intended at standard doses, increasing exposure to topoisomerase I inhibition in normal tissues and causing severe diarrhea and myelosuppression. This is why UGT1A1 genotyping is recommended before initiating irinotecan-based therapy — patients with substantially reduced UGT1A1 activity may require dose reduction. UGT1A1 is not involved in converting irinotecan to SN-38; that conversion is performed by a different hepatic enzyme. UGT1A1 does not accelerate SN-38 elimination, and there is no iminodiacetic acid toxicity pathway.

Correct Answer

D — Cardiomyocytes are postmitotic and cannot regenerate; each cell lost to doxorubicin-induced injury is permanently gone, so cumulative damage reduces cardiac function irreversibly

Rationale

The key difference between the heart and regenerative tissues like bone marrow is proliferative capacity. Hematopoietic stem cells divide continuously; after doxorubicin-induced myelosuppression, surviving progenitors repopulate the marrow and blood counts recover. Cardiomyocytes are postmitotic — they do not divide in adult life. When doxorubicin injures or destroys cardiomyocytes, those cells are not replaced. As cumulative dose rises over the course of treatment, progressive cardiomyocyte loss reduces myocardial contractile mass and cardiac function declines in a dose-dependent, irreversible fashion. This is why lifetime cumulative doxorubicin dose is tracked and capped. Differential drug accumulation, cardiac-specific topoisomerase isoforms, and strand-break repair differences do not account for the irreversibility of cardiomyopathy.

Correct Answer

B — The cumulative dose threshold for conventional doxorubicin is 450 to 550 mg per square meter; beyond this level the incidence of clinical heart failure rises steeply with each additional 100 mg per square meter because cardiomyocyte loss is irreversible and cumulative

Rationale

Doxorubicin causes irreversible cardiomyocyte loss through oxidative stress and topoisomerase II-beta-mediated deoxyribonucleic acid damage. Because cardiomyocytes are postmitotic cells with limited regenerative capacity, each cycle of doxorubicin-induced injury is permanent and accumulates across the lifetime of therapy. The incidence of clinical heart failure rises steeply above the 450 to 550 mg per square meter threshold — from approximately 1 to 2% at 300 mg per square meter to approximately 7% at 550 mg per square meter and above 18% at 700 mg per square meter. At 480 mg per square meter, this patient is at the upper margin of the conventional threshold, and further dosing carries progressively increasing cardiac risk. The mechanism is irreversible cardiomyocyte loss from cumulative oxidative and deoxyribonucleic acid damage — not drug accumulation from impaired clearance, not P-glycoprotein induction, and not nephrotoxicity.

Correct Answer

B — The lung has low capacity to inactivate bleomycin compared with other tissues, so drug persists and continues to cause oxidative damage to pulmonary cells

Rationale

Bleomycin is inactivated by a hydrolytic enzyme present in many tissues throughout the body. The lung and skin contain much lower levels of this inactivating enzyme than organs such as the liver, which explains why the lung is disproportionately vulnerable despite systemic drug distribution. Drug that reaches the lung is not inactivated efficiently and therefore persists in pulmonary tissue, causing cumulative oxidative damage to alveolar epithelial cells and pulmonary fibroblasts, leading to interstitial fibrosis. This is why baseline and monitoring pulmonary function tests are required during bleomycin-containing regimens, and why supplemental oxygen should be used cautiously in patients with prior bleomycin exposure. Selective active uptake by macrophages, oxygen-driven activation, and surfactant protein binding are not the established explanation for pulmonary selectivity.

Correct Answer

A — Prior bleomycin exposure permanently sensitizes the lung to oxidative injury; high inspired oxygen fractions generate reactive oxygen species that can trigger acute respiratory distress syndrome with reported mortality rates exceeding 50% in severe cases, and there is no established safe interval after bleomycin beyond which normal oxygen fractions can be used

Rationale

Bleomycin-induced pulmonary toxicity sensitizes the lung to oxygen-mediated injury through a mechanism involving impaired antioxidant defenses and preexisting structural changes. In patients with prior bleomycin exposure, high inspired oxygen fractions during anesthesia generate reactive oxygen species at concentrations that exceed the damaged lung's diminished capacity to neutralize oxidative stress, triggering acute respiratory distress syndrome. This complication has a reported mortality rate exceeding 50% in severe cases. The sensitization is permanent — there is no established time after bleomycin beyond which normal inspired oxygen fractions are safe. Inspired oxygen fraction must be maintained at the lowest level consistent with adequate oxygen saturation, typically targeting 93 to 95%, and this requirement must be documented prominently in the anesthetic plan and communicated to all perioperative team members. The mechanism is not bleomycin storage, surfactant inhibition, or angiotensin-converting enzyme upregulation.

Correct Answer

C — Topoisomerase II inhibitors such as etoposide cause secondary AML with short latency (1–3 years) and no preceding myelodysplastic syndrome phase; alkylating agents cause secondary AML with long latency (5–7 years) preceded by myelodysplastic syndrome

Rationale

Secondary acute myeloid leukemia caused by topoisomerase II inhibitors (etoposide, doxorubicin) has a characteristic short latency of approximately 1–3 years after treatment and arises de novo without a preceding myelodysplastic syndrome phase. By contrast, secondary acute myeloid leukemia caused by alkylating agents (cyclophosphamide, chlorambucil, melphalan) typically presents 5–7 years after exposure and is almost always preceded by a myelodysplastic syndrome phase with cytopenias and dysplastic marrow changes. Recognizing this clinical pattern allows the treating physician to distinguish the likely causative agent class even years after treatment. UGT1A1 polymorphism is relevant to irinotecan toxicity, not to secondary AML risk. The two drug classes do not reverse latency, and both do not cause myelodysplastic syndrome as a precursor.

Correct Answer

B — The lung has limited capacity to inactivate bleomycin, allowing persistent drug accumulation in pulmonary tissue that causes ongoing oxidative damage and fibrosis

Rationale

Bleomycin is selectively toxic to the lung because pulmonary tissue has low capacity to inactivate the drug compared with organs such as the liver. Drug that reaches the lung persists, generating oxidative damage to alveolar epithelial cells and stimulating pulmonary fibroblasts to deposit collagen. The clinical result is interstitial fibrosis, presenting as the dyspnea, dry cough, bilateral infiltrates, and reduced diffusion capacity seen in this patient. Bleomycin pulmonary toxicity is cumulative and dose-dependent; it is also exacerbated by high inspired oxygen concentrations — a practical concern during anesthesia or intensive care in patients with prior bleomycin exposure. Alveolar macrophage concentration causing granulomas, direct collagen cross-linking, and selective type I pneumocyte destruction are not the mechanism.

Correct Answer

D — Cardiomyocyte loss from doxorubicin is irreversible and accumulates with each dose; tracking cumulative exposure prevents exceeding the threshold above which clinically significant cardiomyopathy becomes likely

Rationale

Because cardiomyocytes cannot regenerate, every dose of doxorubicin that injures cardiac muscle causes a permanent, incremental loss of contractile cells. As cumulative dose rises, this progressive loss eventually reduces ejection fraction to a clinically significant degree — manifesting as congestive heart failure that may appear months to years after treatment is complete. Tracking and capping cumulative lifetime dose reduces the probability of crossing this threshold; baseline and serial echocardiographic assessment detects subclinical decline before it becomes symptomatic. Doxorubicin's cardiac risk is not related to hepatic enzyme saturation, immune sensitization, or tumor drug accumulation.

Correct Answer

A — Topoisomerase II inhibitors such as etoposide characteristically cause secondary AML with a short latency of 1–3 years and no preceding myelodysplastic syndrome phase, consistent with this presentation

Rationale

This presentation — acute myeloid leukemia appearing 18 months after etoposide-containing chemotherapy, without a preceding myelodysplastic syndrome phase — is the classic pattern of topoisomerase II inhibitor-related secondary malignancy. Topoisomerase II inhibitors (etoposide, doxorubicin) cause secondary AML that arises de novo, with a latency of 1–3 years and no myelodysplastic syndrome precursor. This stands in sharp contrast to alkylating agent-related secondary AML, which has a longer latency of 5–7 years and is almost always preceded by a myelodysplastic syndrome phase with cytopenias and dysplastic marrow findings. Recognizing this distinction is clinically important because the two patterns implicate different components of a complex chemotherapy regimen. The acute onset without myelodysplastic syndrome phase argues strongly against alkylating agent causation and against de novo leukemia as a coincidental finding.

Correct Answer

C — Use the lowest inspired oxygen fraction that maintains oxygen saturation at 93 to 95%, because prior bleomycin exposure permanently impairs pulmonary antioxidant defenses and there is no established safe interval after which normal oxygen fractions can be used, even in emergency settings

Rationale

Bleomycin permanently impairs pulmonary antioxidant defenses through loss of functional pneumocytes and disruption of redox homeostasis in remaining cells. High inspired oxygen fractions generate reactive oxygen species that exceed the damaged lung's diminished capacity to neutralize oxidative stress, triggering acute respiratory distress syndrome with mortality rates reported to exceed 50% in severe cases. There is no established safe interval after bleomycin beyond which normal inspired oxygen fractions are safe — the sensitization is considered permanent. In an emergency setting, this does not mean oxygen is withheld: the correct approach is to use the lowest fraction consistent with adequate oxygenation, targeting saturation of 93 to 95%, rather than defaulting to high fractions out of perceived urgency. A preoperative saturation of 94% on room air confirms that lower inspired oxygen targets are physiologically achievable for this patient. Postponing an emergency laparotomy for pulmonary function testing is not appropriate and would not change oxygen management, because diffusing capacity for carbon monoxide monitoring during bleomycin treatment guides dose decisions, not perioperative oxygen strategy.